Mucopolysaccharidoses (MPS) are rare inherited disorders caused by a deficit of the lysosomal hydrolases involved in the degradation of mucopolysaccharides, also known as glycosaminoglycans (GAGs). They are all monogenic defects, transmitted in an autosomal recessive way, except for MPS type II which is X-linked. The enzymatic deficit causes a pathologic accumulation of undegraded or partially degraded substrates inside lysosomes as well as in the extracellular compartment. MPS generally present with recognizable signs and symptoms to raise a clinical suspicion. However, although they have individual peculiarities, often signs and symptoms may overlap between different MPS types. Therefore, a deeper evaluation of specific disease biomarkers becomes necessary to reach an appropriate diagnosis. This paper stresses the central role of the laboratory in completing and confirming the clinical suspicion of MPS according to a standardized procedure: first, a biochemical evaluation of the patient samples, including qualitative/quantitative urinary GAG analysis and a determination of enzyme activities, and then the molecular diagnosis. We also encourage a constant and close communication between clinicians and laboratory personnel to address a correct and early MPS diagnosis. Keywords: Laboratory tests, Mucopolysaccharides, Glycosaminoglycans, Molecular analysis, Pseudodeficiency, Genetic counselling, Genotype-phenotype relationship, Lysosomal storage disorders

Biochemical and molecular analysis in mucopolysaccharidoses: what a paediatrician must know / Mirella Filocamo, Rosella Tomanin, Francesca Bertola; Amelia Morrone. - In: THE ITALIAN JOURNAL OF PEDIATRICS. - ISSN 1824-7288. - STAMPA. - 16:(2018), pp. 36-45. [10.1186/s13052-018-0553-2]

Biochemical and molecular analysis in mucopolysaccharidoses: what a paediatrician must know.

Amelia Morrone
2018

Abstract

Mucopolysaccharidoses (MPS) are rare inherited disorders caused by a deficit of the lysosomal hydrolases involved in the degradation of mucopolysaccharides, also known as glycosaminoglycans (GAGs). They are all monogenic defects, transmitted in an autosomal recessive way, except for MPS type II which is X-linked. The enzymatic deficit causes a pathologic accumulation of undegraded or partially degraded substrates inside lysosomes as well as in the extracellular compartment. MPS generally present with recognizable signs and symptoms to raise a clinical suspicion. However, although they have individual peculiarities, often signs and symptoms may overlap between different MPS types. Therefore, a deeper evaluation of specific disease biomarkers becomes necessary to reach an appropriate diagnosis. This paper stresses the central role of the laboratory in completing and confirming the clinical suspicion of MPS according to a standardized procedure: first, a biochemical evaluation of the patient samples, including qualitative/quantitative urinary GAG analysis and a determination of enzyme activities, and then the molecular diagnosis. We also encourage a constant and close communication between clinicians and laboratory personnel to address a correct and early MPS diagnosis. Keywords: Laboratory tests, Mucopolysaccharides, Glycosaminoglycans, Molecular analysis, Pseudodeficiency, Genetic counselling, Genotype-phenotype relationship, Lysosomal storage disorders
2018
16
36
45
Mirella Filocamo, Rosella Tomanin, Francesca Bertola; Amelia Morrone
File in questo prodotto:
File Dimensione Formato  
s13052-018-0553-2.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Creative commons
Dimensione 1.18 MB
Formato Adobe PDF
1.18 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1144261
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 31
social impact